VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Emerging lymphoma therapies: bispecific antibodies and CAR T-cells

Stephen Opat, FRACP, FRCPA, MBBS, Monash University, Melbourne, Australia, shares his thoughts on emerging therapies for lymphomas that were presented at ASH 2020. Bispecific antibodies and CAR T-cell therapies have gained traction in early phase trials and are beginning to show promising efficacy results in both low- and high-grade malignancies. New challenges will emerge as to how best to optimize these therapies in the clinical setting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Research payments to institution: Beigene

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter